118089-89-7

Usage

Uses

Used in Organic Synthesis:
1-(bromoMethyl)-4-((trifluoroMethyl)sulfonyl)benzene is used as a reagent in organic synthesis for the preparation of pharmaceuticals and agrochemicals. Its unique functional groups contribute to the development of various fluorinated organic compounds with specific properties.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(bromoMethyl)-4-((trifluoroMethyl)sulfonyl)benzene is used as a building block for the synthesis of fluorinated organic molecules with desirable properties, such as enhanced bioavailability and pharmacological activity.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 1-(bromoMethyl)-4-((trifluoroMethyl)sulfonyl)benzene is utilized as a precursor for the development of fluorinated compounds with improved pesticidal properties, such as higher stability and effectiveness against pests.

Upstream product

• 383-10-8 1-methyl-4-(trifluoromethylsulfonyl)benzene 
• 219872-98-7 4-(trifluoromethylsulfonyl)benzyl alcohol 
• 352-68-1 4-trifluoromethylthiotoluene 
• 650-89-5 (4-trifluoromethanesulfonyl)-benzaldehyde 
• 56456-52-1 (4-((trifluoromethyl)thio)phenyl)methanol 
• 21101-63-3 4-(trifluoromethylthio)benzyl bromide 

Downstream Products

• 194222-98-5 p-trifluoromethanesulfonylbenzyltriflone 

Relevant academic research and scientific papers

Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases

Optimization of a 7-azaindole-3-acetic acid CRTh2 receptor antagonist chemotype derived from high throughput screening furnished a highly selective compound NVP-QAV680 with low nM functional potency for inhibition of CRTh2 driven human eosinophil and Th2 lymphocyte activation in vitro. The molecule exhibited good oral bioavailability in the rat, combined with efficacy in rodent CRTh2-dependent mechanistic and allergic disease models and was suitable for clinical development.

TEAD INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

COLD MENTHOL RECEPTOR-1 ANTAGONISTS

The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

A novel synthesis of deactivated benzylic triflones

A two-step synthesis of benzylic triflones, based on the reaction of 2.4.6-trisubstituted phenyl halides 3a-f with the anion of ethyl (trifluoromethanesulfonyl)acetate 1 followed by a decarboxylation reaction, is reported. The structural assignments are s